BridgeBio Pharma BBIO Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 95.1%-0.2pp | 95.8%-2.4pp | 95.8%-3.1pp | 96.2%-2.7pp | 95.4%-3.6pp | |
| Operating margin | -90.5%+457pp | -104.2%+163pp | -172.4%+77.6pp | -278.4%-45.5pp | -547.6%-328pp | |
| Net margin | -125.9%+405pp | -146%+98.9pp | -227.7%-22.8pp | -332.9%-122pp | -531.2%-281pp | |
| EBITDA margin | -89.6%+453pp | -103.2%+161pp | -170.9%+76.2pp | -276%-46.1pp | -543%-326pp | |
| Free cash flow margin | -76.8%— | -89%— | -165.6%— | -278.4%— | —— | |
| Returns | ||||||
| Return on assets | -64.8%+13.4pp | -79%-4.9pp | -96.9%-29.3pp | -83.8%-12.6pp | -78.2%-4.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×+0.4× | 0.5×+0.2× | 0.4×+0.1× | 0.3×-0.1× | 0.1×-0.1× | |
| Inventory turnover | 1.5×— | —— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 1.5×-3.0× | 2.8×-1.9× | 3.9×+0.7× | 5.2×+0.6× | 4.6×-1.0× | |
| Quick ratio | 1.5×-3.1× | 2.7×-2.0× | 3.8×+0.6× | 5.1×+0.5× | 4.5×-1.0× | |
| Cash ratio | 1.1×-2.5× | 0.6×-3.8× | 3×0.0× | 4.3×+1.2× | 3.6×+0.2× | |
| Leverage | ||||||
| Debt-to-assets | 2.4×+2.4× | 0×-0.5× | 2.1×+1.4× | 0×-0.6× | 0×-0.5× | |
| Interest coverage | -7.1×+1.0× | -6.6×-0.1× | -6.9×-0.8× | -6.5×-0.7× | -8.1×-2.5× | |
| Per Share | ||||||
| Book value per share | -$11.70-34.9% | -$10.89-38.1% | -$10.08-54.4% | -$9.38-61.1% | -$8.67-47.6% | |
| Valuation | ||||||
| Market capitalization | $14.4B+119% | $14.74B+184% | $9.93B+107% | $8.44B+78.1% | $6.57B+15.3% | |
| Enterprise value | $16.77B+178% | $14.58B+195% | $11.34B+135% | $7.7B+61.1% | $6.04B+6.5% | |
| Price / sales | 24.8×-26.8× | 29.4×+6.0× | 28.1×+6.1× | 35.8×+14.2× | 51.6×+25.5× | |
| EV / sales | 28.9×-18.5× | 29×+6.7× | 32.1×+9.9× | 32.7×+10.8× | 47.4×+21.5× | |
| Free cash flow yield | -3.1%— | -3%— | -5.9%— | -7.8%— | —— | |
| Earnings yield | -5.1%+5.2pp | -5%+5.5pp | -8.1%+1.2pp | -9.3%+0.4pp | -10.3%-0.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are BridgeBio Pharma's profit margins?
- BridgeBio Pharma (BBIO) runs a 95.1% gross margin and a -90.5% operating margin, with a -125.9% net margin.
- Where do BridgeBio Pharma's ratios come from?
- Every ratio is computed from BridgeBio Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
